Lifetime risk of developing colorectal cancer is 5%, and 5-year survival at early stage is 92%. Individuals with precancerous lesions removed at primary screening are typically recommended surveillance colonoscopy. Because greater benefits are anticipated for those with higher risk of colorectal cancer, scope for risk-specific surveillance recommendations exists. This review assesses published cost-effectiveness estimates of postpolypectomy surveillance to consider the potential for personalized recommendations by risk group. Meta-analyses of incidence of advanced neoplasia postpolypectomy for low-risk cases were comparable to those without adenoma, with both rates under the lifetime risk of 5%. This group may not benefit from intensive surveillance, which risks unnecessary harm and inefficient use of often scarce colonoscopy capacity. Therefore, greater personalization through deintensified strategies for low-risk individuals could be beneficial. The potential for noninvasive testing, such as fecal immunochemical tests, combined with primary prevention or chemoprevention may reserve colonoscopy for targeted use in personalized risk-stratified surveillance. This review appraised evidence supporting a program of personalized surveillance in patients with colorectal adenoma according to risk group and compared the effectiveness of surveillance colonoscopy with alternative prevention strategies. It assessed trade-offs among costs, benefits, and adverse effects that must be considered in a decision to adopt or reject personalized surveillance.
INTRODUCTION
Lifetime risk of developing colorectal cancer is 5% for an average risk individual in the United States (1) . Colorectal cancer is the third most common cancer globally and imposes a significant burden of ill health (2) . Worldwide, colorectal cancer deaths form 8.5% of total cancer deaths (694,000 annually) (3) . Many deaths could be avoided by early detection through screening (4, 5) ; as given, the 5-year relative survival rates for colorectal cancer detected at a local stage are 92% (6) .
Screening programs have been widely implemented to manage colorectal cancer risk (7) . Such programs use colonoscopy either as the primary test or as a diagnostic test following a positive finding on a noninvasive stool test, which detects blood or other markers suggestive of cancerous lesions.
Colonoscopy offers direct visualization and examination of the entire colon, permitting the identification and removal of polyps leading, it is thought, to the prevention of colorectal cancer (5) .
There are concerns over claims that screening programs reduce mortality or improve survival (8) , based largely on arguments related to lead time bias. Lead time bias occurs when a diagnostic test merely identifies the disease earlier, thus increasing perceived survival without significant modification of the disease course (9) . Despite such concerns, a recent meta-analysis of randomized screening trials (which addressed the effect of lead time bias) showed that 1 colorectal cancer death is prevented for every 1,000 people screened, with this benefit being manifest on average after 9.4 years (9, 10) . Moreover, microsimulation modeling is reported to show that declines in colorectal cancer death rates are consistent with a relatively large contribution from screening (11) . Although there is considerable randomized control trial evidence to support screening overall, the magnitude of benefit from surveillance (in terms of colorectal cancer deaths prevented) is uncertain.
Postpolypectomy surveillance by colonoscopy has become a common feature of colorectal cancer prevention strategies (12, 13) , offering intensive monitoring to individuals with prior precancerous findings at primary screening (14) . In the case of colorectal screening, appropriate surveillance after endoscopic diagnosis of an adenoma (15) is typically a strategy of surveillance colonoscopy at intervals of between 3 and 10 years. Surveillance intensity can be adjusted depending on an individual's estimated colorectal cancer risk, as predicted by the number and grade of polyps removed at index colonoscopy. Despite being widely recommended, the evidence that postpolyp surveillance reduces colorectal cancer incidence or mortality is lacking and is rarely established for subgroups (16) .
Up to 85% of colorectal cancers are thought to develop from conventional adenomas (17) . Adenomas begin in the glandular tissue lining the colon and, while many are benign, some may have malignant potential. Genetic changes in the colon's lining can lead to malignancy as a result of a complex multistep process in which adenoma is an intermediate stage.
A process referred to as the "adenoma-to-carcinoma sequence" takes an estimated 7-15 years (17) (18) (19) (20) . The long preclinical sojourn time of many adenomas creates the opportunity for successful early detection through screening. Reported adenoma prevalence is estimated at 20%-53% in persons over 50 years, with sex differences showing higher prevalence in men (40%) than in women (29%) (17, 21) .
Colonic polyps were conventionally classified as either hyperplastic or adenomatous, of which the latter were believed to have the potential to progress to carcinoma (22) . Advances in genetic pathology are alleviating so-called "variant classification" that "obfuscated the correct classification" of sessile serrated adenomas (23) , which unfortunately were not as readily detected by many screening tests. As new information emerges, it is possible that sessile serrated lesions may be responsible for up to 30% of colorectal cancer. The implications of the different pathologies for clinical management warrant the vigilance of physicians who may consider follow-up colonoscopies in accordance with guidelines for sessile serrated adenomas (24) (25) (26) (27) . Although sessile lesions may have greater contribution to colorectal cancer than previously thought, this review focuses on the evidence related to adenomatous polyp risk groups.
Although there is limited decisive evidence from colonpolyp surveillance, current guidelines for postpolypectomy surveillance use explicit risk stratification by subgroups, using the predictive features of adenomas detected at screening colonoscopy (28) . The size, the number of polyps, and their histology provide further qualification in differentiating those with tubular features from those with villous features, considered more likely to have cancers develop in them (29) . For example, US guidelines recommend that individuals with 3-10 adenomas undergo a surveillance colonoscopy every 3 years, while those with 1-2 tubular adenomas <10 mm receive a surveillance colonoscopy every 5-10 years (30) . Surveillance colonoscopies account for approximately 25% of colonoscopies among people aged over 50 years in the United States (31) .
Although the surveillance guidelines are clear, conflicting reporting might lead to a conclusion that these persons are at a significantly increased risk, while other reports contend that many of the lesions detected at screening are likely to be of low risk. It has been suggested that following initial detection and removal of adenomas, approximately half of people (51.4%) will have further adenomas within 3 years of initial colonoscopy, of which significant numbers may meet at least 1 criterion for advanced adenoma (13, (32) (33) (34) (35) . However, 84% of all polyps removed at colonoscopy in a large screening study of 13,992 participants were less than 10 mm. Within a subset of the study population, colorectal cancer was detected in 0.03% of participants whose largest polyp was 1-5 mm (1 patient among 3,744 patients with polyps 1-5 mm in size); moreover, only 3 of the 74 cancers detected were found as a consequence of detecting advanced adenomas (17, 36) . Consequently, screening typically generates many "positive" findings that ultimately may be of low risk, accounting for a small portion of cancer cases, meaning that large numbers of patients will be referred to surveillance, the clinical utility of which can be debated (17, 36) .
Although 1 benefit of surveillance is the possibility to detect lesions of significance, it may expose patients to unnecessary risks as a result of overdiagnosis, that is, the inclusion of "pseudodisease" that would not become evident before the patient dies of other causes (37) . For example, it was reported that colorectal cancer was diagnosed in 19 of 2,915 patients who were deemed free of remaining lesions at a baseline clearing colonoscopy, over a mean follow-up of 3.7 years (incidence, 1.74 cancers/1,000 person-years) among those in close surveillance. Equating to 0.65% of atypical postpolypectomy surveillance participants developing colorectal cancer (38) , this includes a considerable number of individuals who undergo a surveillance test(s) who could therefore be considered subject to overdiagnosis.
Some regions are adopting resect and discard policies, whereby lesions judged by the clinician performing polypectomy thought not to be of high risk can be discarded without being evaluated by a pathologist, thus reducing the risk of procedure overdiagnosis (39) . Another obvious means to lower potential overdiagnosis and limit the harms of invasive testing might be to consider an alternative to colonoscopy and to personalize approaches to surveillance by exploring the role of fecal immunochemical testing (FIT) (40) . In a recent systematic review, FIT showed high diagnostic accuracy for detecting colorectal cancer, and it has shown the capability of quantifying and adjusting cut-off concentrations for positivity (41) (42) (43) . Moreover, its acceptability to patients has also been demonstrated (44) . Therefore, FIT could be an appropriate, acceptable, and cost-effective surveillance test.
Decision making requires careful balancing to avoid either too little surveillance, which may jeopardize colorectal cancer prevention goals or lead to overuse of surveillance, chancing unnecessary harms and inefficient use of colonoscopy resources (45) . Health economic evaluations aim to impartially identify, measure, and compare the cost and consequences of the different interventions being considered to manage particular clinical problems (46) . Recent economic evaluation in the United States estimated an inflection point between conferring benefit and risking harm in the use of colonoscopy in older adults (47, 48) , whereby the anticipated harms of false positives and unnecessary investigations outweighed the benefits of early detection.
The relevant resource utilization relates to not only the financial costs of providing surveillance but also colonoscopy capacity, which is often constrained in many health systems. Therefore, decision makers need to consider how best to allocate the limited number of colonoscopy examinations to those individuals with the greatest likelihood of benefit.
Consensus has not yet emerged on what personalized surveillance practice ought to involve, with variation in current guideline recommendations shown in Table 1 . For example, Japan does not differentiate its surveillance guidance by risk category, recommending colonoscopy every 3 years, whereas recommendations from the United Kingdom vary between a 1-year colonoscopy for high-risk patients and a 5-year colonoscopy (or return to screening in 2 years) for low-risk patients. Concerns over how best to balance surveillance intensity will be increasingly pressing given the anticipated growth in numbers of people being directed into surveillance colonoscopy (14) , in part the result of demographic aging and changes in the primary screening technology utilized. Current data suggest that screening colonoscopy may identify patients at low risk of death from colorectal cancer or who may derive greatest value from a single screening test, but who may not benefit from subsequent intensive surveillance (49, 50) . Although meta-analysis of the incidence of advanced neoplasia after polypectomy for a low-risk individual is comparable to that of persons without findings of an adenoma at colonoscopy, the absolute risk in both groups was less than the average person's lifetime risk of 5% (low risk = 3.6% vs. without adenoma = 1.6%) (51) . This indicates that the low-risk group may indeed have a colorectal cancer risk that is broadly comparable to that of the average-risk population eligible for primary screening. For that reason, there may be arguments for deintensifying surveillance toward the types of screening frequencies and noninvasive testing technologies used in primary screening, which in turn would lead to greater personalization of colonoscopy use.
Existing approaches to the adjustment of surveillance intensity rely on the frequency of testing, that is, through changes to the interval of use of the current technology (colonoscopy), offering, for example, 3-and 5-10-year colonoscopy (30) . The ability to vary surveillance has been limited to this interval approach. Newer, more effective stool tests may offer the ability to change the type of test offered, which may add flexibility to surveillance programs and, as a result, reduce the number of colonoscopies required during surveillance.
Accordingly, this systematic review has 3 aims:
1. To assess if there is sufficient evidence to evaluate a program of personalized surveillance in patients with colorectal adenoma according to risk subgroup. 2. To compare the effectiveness of surveillance colonoscopy with alternative prevention strategies. 3. To assess trade-off among costs (resource use), benefits, and adverse effects that need to be considered in a decision to adopt or reject personalized surveillance.
METHODS

Data sources and search strategy
This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) guidance recommendations (52, 53) and the Centre for Reviews and Dissemination guidance (46) . Details of the protocol for this systematic review were registered on PROSPERO: international prospective register of systematic reviews and can be accessed at http:// www.crd.york.ac.uk/PROSPERO/display_record.asp?ID= crd42016033509. An initial check for previous reviews on the topic was conducted, as recommended (46, 54) . The search for the key words "adenoma" AND "cost" in ANY FIELD (September 2015) was carried out within the 3 Centre for Reviews and Dissemination (CRD) databases (Database of Abstracts of Reviews of Effects (DARE), National Health Service Economic Evaluation Database (NHS EED), and Health Technology Assessment (HTA) database), those most specific to economic evaluations of health and social care interventions (55) . This search indicated no existing systematic reviews addressing cost-effectiveness within colorectal adenoma surveillance and prevention programs.
The systematic review search strategy was optimized with help from a Specialist Medical Librarian (R.F.), informing the choice of available databases and developing the search to meet the needs of the review. The search strategy was run in MEDLINE, MEDLINE in-process, and EM-BASE. These databases were searched from their inception to February 2016 for key words, medical subject heading terms, and synonyms of the following:
1. Colorectal neoplasms OR adenoma. 2. Costs-benefit analysis OR synonyms. 3. Early detection of cancer OR surveillance. Searches 1, 2, and 3 were then combined with AND, as shown in Web Appendix 1 (available at http://aje.oxfordjournals. org/).
In order to optimize the resultant yield of studies, we expanded the medical subject heading terms, used a modified strategy in each database (MEDLINE/EMBASE) to identify the literature under relevant terms, and included techniques for word proximity and suffixes, which optimized database search tools to find relevant papers.
The titles and abstracts of the studies returned by the database searches were then screened for inclusion by eligibility criteria according to the patient population or the disease being addressed (P), the interventions or exposure (I), the comparator group (C), the outcome or endpoint (O), the study date/time frame (T), and the study design chosen (S) (designated "PICOTS") (56), as shown in Table 2 . The reference lists of the retrieved studies were searched to find studies not captured by our database searches.
Study selection was conducted in 3 stages, as shown in Figure 1 , including removal of duplicates (n = 264), title and abstract screening against the PICOTS criteria (n = 1,010), and independent screening of all full-text articles (n = 32) to confirm their eligibility, by 2 reviewers (E.M.F, J.F.O.M.), conducted according to the selection criteria detailed in Web Appendix 2. In order to minimize bias, studies were retained in situations where both reviewers were not in agreement on exclusion, with discrepancies resolved by adjudication with a third reviewer. All excluded papers were codified by ineligibility of PICOTS category. This process resulted in 7 papers that were fully evaluated for the review.
Data extraction and identification of cost-effectiveness analyses
We extracted the initial data from each study using the Consolidated Health Economic Evaluation Reporting Standards statement checklist tool (57). We have not conducted a meta-analysis as the outcomes of economic evaluations are typically not commensurate for comparison. Some studies reported incremental cost-effectiveness ratios (ICERs) that differ from the conventional interpretation, as the ratio of incremental costs to incremental health effects, relative to the next most effective strategy (58) , whereby strategies that are more costly and less effective are ruled out by simple or extended dominance (59, 60) . In these instances, the ICERs were recalculated from the reported costs and effects, and replicated cost-effectiveness estimations were used to reexamine the comparisons and analyses made by the studies, as carried out in another recent review (61) . The recalculated results are presented alongside the originally published results in Web Table 1 .
RESULTS
Study descriptions
The systematic review returned 7 papers that were fully evaluated. An overview of the key quality attributes of each paper as assessed in this review is given in Web Table 2 , following the Consolidated Health Economic Evaluation Reporting Standards quality indicators (50, (52) (53) (54) (55) (56) (57) . The studies were published between 1991 and 2011; no studies from more recent years were identified.
In brief, the search returned a small number of studies, and the prevention strategies compared in the studies varied such that not all compared the same alternative interventions. Thus, the potential for cross-comparison of the effectiveness and cost-effectiveness of particular strategies was limited. Although some papers compare surveillance by colonoscopy with natural history, others compared surveillance by colonoscopy with a screening colonoscopy at a 10-year interval (62) or by performing an early 1-year colonoscopy (63) , while other models compared surveillance colonoscopy combined with chemoprevention (64, 65) and chemoprevention alone compared with natural history (66) .
The strategies considered include the following: Case series, case reports, and reports from gray literature and conference proceedings were excluded from the review owing to the high potential for bias. RCTs and controlled trials reported effects, and other formats than controlled trials, cohort studies, and case-control studies considered within the quality evaluation in models are not directly included.
Abbreviations: CTC, computed tomographic colonography; FIT, fecal immunochemical testing; FOBT, fecal occult blood testing; LYG, life-year gained; RCT, randomized controlled trial. a PICOTS, a designation for eligibility criteria according to the patient population or the disease being addressed (P), the interventions or exposure (I), the comparator group (C), the outcome or endpoint (O), the study date/time frame (T), and the study design chosen (S).
b Sessile serrated lesions are often added to guidelines addressing the umbrella term, polyp/adenoma. Clear pathological and molecular distinctions are now recognized; thus, we refer to comprehensive recent work on this pathology for further clinical information (25, 26) .
• Calcium therapy combined with colonoscopy (64), • Fixed-interval/modified-interval colonoscopy surveillance (67) .
Evaluation of included papers vis-à-vis objective
To address the primary aims of the review in a systematic way, the following sections critically address how the respective papers' methods, assumptions, and outputs support or prohibit clear evidence for each objective.
Evidence to support personalized surveillance by subgroup at index colonoscopy. No papers reported costeffectiveness results disaggregated by high-risk/low-risk subgroups. Although 2 studies described clear elements of stratification, identifying high-risk and low-risk subgroups of patients with adenoma, neither reported a comparison of outcomes by these subgroups; rather they reported results as combined group data (59, 64) . Accordingly, this limited what our review was able to determine regarding riskoptimized surveillance strategies. The reporting in 1 paper did permit a stepwise comparison of interval change for surveillance by colonoscopy in high-risk and low-risk groups (62) . The ICERs presented indicated that it is beneficial to change from a 10-year-interval colonoscopy to a 3-year interval for high-risk individuals (62) , as this strategy was more effective and its ICER of $5,743/quality-adjusted life-year indicated that it is a costeffective policy change within conventional thresholds thought to be between $50,000 and $100,000/qualityadjusted life-year (68) . Although it is also beneficial to move from 10-year-interval colonoscopy to a 5-year interval in low-risk individuals, the ICER of $296,266/qualityadjusted life-year is greater than conventionally accepted thresholds for the United States (68) . Importantly, these results also indicated that more intensive surveillance by a change from a 5-year to a 3-year interval for low-risk individuals resulted in reduced quality-adjusted life-years (−0.0023 quality-adjusted life-years). This "disutility of colonoscopy" shows that it becomes more harmful for lowrisk individuals to receive a more intensive surveillance strategy of a 3-year colonoscopy (62) .
Effectiveness of colonoscopy compared with alternative prevention strategies. An important purpose of this review was to find studies that compared alternatives to colonoscopybased surveillance. The review found no studies that considered clinical test strategies in postpolypectomy surveillance other than colonoscopy. All papers retrieved assumed that the default test for surveillance was colonoscopy. There are, however, comparisons of colonoscopy with 3 types of chemoprevention drugs, all of which compared chemoprevention benefit with no intervention (64, 65) or compared colonoscopy combined with chemoprevention with no intervention (64, 65) . A summary of the results from the strategies evaluated for surveillance is shown in Web Table 1 .
In addressing clinical variations in colonoscopy capacity, the most recent paper authored by Wilschut et al. (59) used the Microsimulation Screening Analysis (MISCAN)-Colon model (1 of 3 internationally validated models that evaluate screening programs). This included 48 variations of the background screening program within which 2 surveillance strategies were simulated. Although this study presented results for variation in the primary screening strategy, the reported results do not permit comparison of the 2 surveillance strategies considered. The analysis considered whether it would be appropriate to offer colonoscopy surveillance under increasingly tight colonoscopy capacity constraints. They found that an affordable ICER was achievable for colonoscopy surveillance when capacity was greater than 20 colonoscopies per 1,000 individuals (59). However, if the capacity of colonoscopy was <5 per 1,000 individuals offering low-risk groups surveillance, colonoscopy was no longer considered an effective allocation of a scarce health resource (59) .
The analysis by Wilschut et al. (59) adds a modelling feature, not commonly used in the other papers, that permits the simulation of the impact of both primary screening and subsequent surveillance. Moreover, it has the ability to evaluate issues of service capacity, alternate types of testing, and a mix of tests that more accurately reflects the complexity of choice facing decision makers. By comparison, the models used in the other reviewed studies characterize only limited aspects of the decision problem.
Hassan et al. (63) estimated the benefit of early annual colonoscopy compared with not doing an early annual colonoscopy. Because their descriptions are not clear, we clarify that they compare providing a 1-year with a 3-year test. They report an ICER of $66,136 per life-year gained (LYG) for a comparison of annual colonoscopy with no yearly test (63) (where "no test" is modelled as a 3-year test). However, the paper did not report total costs or total effects for the strategies considered; consequently, it was difficult to assess this ICER or its basis. The modelling conducted in this comparison is for persons aged 60 years on entry to the surveillance program. This comparison may have somewhat limited clinical relevance in its chosen setting, as the recommended age to start screening in the United States is 50 years (7). The finding that an annual colonoscopy may be cost-effective relative to a 3-year colonoscopy is in keeping with the results of an application of the United Kingdom guidelines in the United States which suggested that a subset of high-risk patients may warrant a 1-year clearing colonoscopy (69) .
Chemoprevention. Although none of the reviewed studies considered tests other than colonoscopy, a range of chemoprevention strategies was evaluated (64) (65) (66) , 1 of which demonstrated that a strategy using aspirin combined with colonoscopy is cost-effective (65) . Focusing on the absolute differences in benefit, this study estimated that, compared with no intervention, colonoscopy surveillance accrued 0.0124 life-year saved (LYS) while aspirin combined with colonoscopy surveillance provided 0.0138 LYS (65) .
DuPont et al. (65) reported ICERs for aspirin alone, colonoscopy surveillance alone, and a combined intervention of aspirin with colonoscopy surveillance, which showed ICERs of $87,609/LYS, $78,226/LYS, and $60,492/LYS, respectively. These ICERs, however, appear to have been calculated differently from the conventional interpretation (58) . As such, the reported ICERs in the paper are effectively average cost-effectiveness ratios, that is, ratios of the cost to benefit of interventions without reference to a comparator (70) . Accordingly, we recalculated the ICERs from the reported costs and effects, and the replicated cost-effectiveness estimations were plotted on a cost-effectiveness plane. These reestimated ICERs are reported in Web Table 1 alongside the reported values from the paper. This reinterpretation of the results indicates that aspirin chemoprevention alone was subject to extended dominance, as was colonoscopy surveillance alone, meaning that they are not preferred from the cost-effectiveness perspective. The combination of 3-and 5-year-interval colonoscopies combined with aspirin had an ICER of $73,927/LYS. This result shows that combination therapy is more efficient than either intervention alone, which is noteworthy and merits further investigation, given the role of aspirin in the prevention of premature mortality due to other causes.
Arguedas et al. (66) compared colonoscopy surveillance with no surveillance and demonstrated an incremental benefit of 0.01995 LYS (8.48482 life-years vs. 8.45487 life-years), while celecoxib was estimated to provide a greater absolute gain in LYS, generating a further 0.00579 LYS relative to colonoscopy surveillance. Although celecoxib chemoprevention was estimated to be more effective than colonoscopy, the ICER of $1,715,199/LYS was significantly above US thresholds (68) .
Notably the DuPont et al. (65) aspirin paper and the Arguedas et al. (66) paper evaluating chemoprevention using celecoxib shared coauthors and used similar models. Although the title of the DuPont et al. paper described addressing increased risk for colorectal cancer, the title of the Arguedas et al. paper described average-risk patients; however, both models explained colonoscopy surveillance as colonoscopy occurring 3 years after index colonoscopy (65, 66) . Such a description left it unclear if individuals eligible for a 5-year surveillance test were included. Whether these models in fact incorporated only those in the high-risk group, according to US guidelines (30), was not fully supported by the parameter estimates for the models. The cited reference (66) for a malignant transformation rate of 0.10 was taken from published data for untreated polyps, rather than reported high-risk transformation. The probability reported differed in the aspirin analyses, where malignant transformation was reported as 0.01, citing 1 shared reference. Consequently, in the absence of clear reporting, we cannot draw any firm conclusions about whether all those eligible for surveillance were modelled in either paper.
The effectiveness of supplemental calcium as a chemoprevention was evaluated by Shaukat et al. (64) . That analysis assessed a dose of 1.2 g/day for ages 50-80 years, not at the 3-4 g/day dose mentioned in the article as providing a reduction in adenoma recurrence of 22% compared with placebo in meta-analyses. The article does not present a clear argument for using the lower dose selection.
Like DuPont et al., Shaukat et al. (64) report an ICER for calcium chemoprevention alone. However, this strategy is subject to extended dominance and so would not be a preferred strategy and should not have an ICER reported for it. The recalculated ratios of costs and effects were replicated to provide cost-effectiveness estimations that were plotted on a cost-effectiveness plane, reported in Web Table 1 . Based on the recalculated ratios, the resultant ICER for surveillance colonoscopy was $20,494/LYG when compared with natural history, with the combination of calcium chemoprevention and colonoscopy generating an ICER of $2,823,333/LYG based on the 0.0003 incremental LYG reported (64) , an ICER that is once again greater than the conventional US thresholds (68) .
This reassessment of the reported results indicated that surveillance colonoscopy alone is cost-effective, while the ICERs indicated that the incremental cost of additional health benefits from chemoprevention by celecoxib alone or calcium combined with colonoscopy was likely to be very high relative to the health gains. It can tentatively be claimed that aspirin chemoprevention combined with surveillance colonoscopy appears to be cost-effective but, given the ambiguity regarding risk groups within the DuPont et al. paper, the results merit further investigation to clarify if these are subgroup dependent or if they might apply to all adenoma patients.
From the review, we believe the salient points from the conclusions of these cost-effectiveness evaluations of colonoscopy-based surveillance programs to be the following:
1. Colonoscopy capacity can, at lower levels, prohibit the ability of health systems to offer colonoscopy-based surveillance to low-risk groups (59). 2. Compared with a 10-year low-risk colonoscopy, offering a 5-year colonoscopy to low-risk groups was above US thresholds at $296,266/quality-adjusted life-year (62). 3. Compared with a 3-year high-risk colonoscopy, a 1-year high-risk colonoscopy for persons aged 60 years entering surveillance has supportive evidence (63). 4. Aspirin combined with surveillance colonoscopy generated greater life-years saved than aspirin or colonoscopy alone and, given its role in the prevention of premature mortality due to other causes, this combination merits further evaluation.
There were quality and reporting issues with a number of the papers evaluated. These shortcomings suggest that questions remain regarding the cost-effectiveness of postpolypectomy surveillance programs.
The trade-off between costs (resource use) and beneficial or adverse effects that needs to be considered in a decision to adopt or reject personalizing surveillance. Cost calculations of the strategies should account for all resources used. Although all models included the costs of colonoscopy and polypectomy, program and administration costs were described in only 2 papers (59, 62) . Only 1 reviewed study attempted to address the treatment costs, accounting for newer therapies such as oxaliplatin, now recommended in advanced stage cancer, and terminal care costs (59, 71, 72) . Where these costs were estimated for the final year of life, there was some uncertainty as to how these were adjusted for according to heterogeneity by stage (59) . There was no consistent approach to adjusting treatment costs according to the stage of disease (62) (63) (64) 72) . Adjustments for inflation were also unclear in some of the papers (59, 67) . Use of biologics, such as cetuximab or bevacizumab, in treatment costs assumptions was not noted.
Study costs were commonly taken from Medicare fee schedules for colonoscopy, polypectomy, complications and pathology (62) (63) (64) (65) (66) , or in some cases national reports (62) . Only 1 study reported the type of distribution used for costs in probabilistic sensitivity analyses (62) . Indirect costs, in the form of lost income to the patient and an escort, were included in only 1 study (63) . Somewhat surprisingly, 1 study cited a long-term arthritis trial for their $100,000 cost per colorectal cancer case, the provenance of which was uncertain given the source cited (66) .
Resource costs for aspirin were given from a trial with wholesale prices used in sensitivity analyses (65) . Calcium costs were described as constant over the period [2005] [2006] [2007] [2008] prices (64) . There were some inconsistencies in referenced costs for "incurable" colorectal cancer (65) , citing a base case scenario of $40,000 with a maximum in the range of $100,000 from a source that used this maximum as its base case (66) .
Health effects were calculated on the basis of the estimated effect of colonoscopy and polypectomy and weighted by the risk of adenoma transformation in all models. The use of a preference-weighted health-state classification system, such as EuroQol-5D (a descriptive system comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) (73), was not consistently reported. No citations were presented for the utility estimates used in some models (for colorectal cancer at diagnosis and subsequently) (59) , while in others no measures for utility were given (63) .
We noted a large difference in the modelled life expectancy (between 8.45487/LYS (66) and 12.2847/LYS (65)) under no surveillance of celecoxib and aspirin from 2 studies that used related models in which the same discount rate was used and individuals were modelled from age 50 in both cases. Although the difference in life expectancy may relate to differences in risk subgroups between the analyses, the difference still seems large and was not readily explained. Although there is a 6-year gap in publishing, it is unclear whether this difference can be directly attributed to the characteristics modelled, surveillance program, differences in the quality or practice of colonoscopy techniques over time (24, 74) , or treatment improvements (72) .
It is inevitable that colonoscopy carries the risk of missed lesions, given as approximately 22% by metaanalyses (75, 76) . Missed polyps clearly have the potential to become interval cancers. Only 2 of the studies (62, 65) reported the probability of a missed polyp, and there was a noticeably large variation ranging from 0.08 to 0.21 (where reported as a percentage, small adenoma = 17.8% and large adenoma = 4.6% (64) ). The remaining studies have not reported this within model parameters, and it thus implies it is not assessed within the analyses (59, 63, 66) .
The risk of colonic perforation, as an adverse effect, was considered in all but one of the models (63) . This was modelled with various probabilities: a base case probability of 0.0006 (62), 0.003 for colonoscopy alone (65, 66) , or 0.02 with polypectomy (66) . The origins of these rates are uncertain from the reported literature. Although relatively rare, perforation can cause significant morbidity and even death (30-day morbidity rates of 21%-53% and mortality rates of 0%-26%, with hospital stay of up to 3 weeks (77)).
DISCUSSION
The main policy-relevant issue emerging from this review was that no studies were found that evaluated the costeffectiveness of colonoscopy against other tests, such as FIT or other noninvasive testing. Colonoscopy has been the primary approach to postpolypectomy surveillance since the early 1990s, but it has not been compared with other tests in the surveillance of patients after polypectomy. This is in spite of the availability of alternatives, such as FIT, which have been compared with colonoscopy in index screening evaluations (78) (79) (80) (81) (82) .
Critically, we acknowledge the gaps in cost-effectiveness reporting by subgroup. Because it is possible to implement different treatment decisions for patients with different characteristics, models should consider the potential for their results to vary across different subgroups to facilitate different policy decisions (83) . As demand for testing changes over time in screening programs through the introduction of newer technologies and with trends in adherence and a variable adenoma detection rate (84), these issues require attention from policy makers and modelers to understand and explore the potential of modelling to provide a clear understanding of the risks and benefits in the choice of interventions adopted.
Prior work has shown that the FIT threshold for positivity can be adjusted within a screening program to optimize detection according to available colonoscopy capacity (85) . Therefore, postpolypectomy surveillance could follow such an approach. The role of FIT is being considered in surveillance with a trial in the United Kingdom currently comparing FIT versus colonoscopy (86) . FIT offers improved performance over older stool-based testing techniques, and its ability to adjust cut-off levels may allow for greater optimization of resources given colonoscopy capacity constraints.
The NHS Bowel Cancer Screening Program from the United Kingdom recently recommended that the primary test used be changed from guaiac-based fecal occult blood testing to FIT (87) (88) (89) . Such a change in the primary test used will likely affect the numbers of patients detected with advanced adenoma and, with it, those eligible for surveillance (90) . As part of this change, there are planned adjustments to the FIT positivity cut-off value used, in order to continue to optimize the effectiveness of the planned technology in line with capacity changes and service transition. These recommendations have acknowledged the likely systemic effect on colonoscopy capacity; as such, it would seem pragmatic to consider not only the adjustment of the FIT cut-off for screening but also its role within the surveillance context. Whether surveillance guidelines might be developed or modified to account for colonoscopy capacity is 1 issue that might be explored in future modelling studies.
FIT has the potential to be an effective postpolypectomy surveillance test for suitable risk groups. Reported uses in screening other high-risk groups (e.g., first-degree relatives of patients with colorectal cancer) have revealed that annual FIT screening (over 3 years) detected all colorectal cancers and proved equivalent to colonoscopy in detecting advanced neoplasia (91) . FIT, when used between scheduled surveillance colonoscopies, has been shown to have detected neoplasia sooner than scheduled surveillances (92) . Interval FIT analyses could be effectively used to detect missed or rapidly developing lesions in surveillance programs (92) . FIT has a useful diagnostic role, and it has also been suggested that FIT has a predictive capacity, with interval cancers independently predicted by fecal hemoglobin concentration, which may be applied for tailored case management and modification based on fecal hemoglobin concentration (93) .
The use of existing tests such as FIT, in innovative and adaptive ways, might help to accrue benefits in more riskappropriate, prescribed, and personalized surveillance-based approaches. Addressing and personalizing other known features of risk of colorectal cancer, such as diet and lifestyle, might offer increased precision and optimize the prevention of colorectal cancer. Offering personalized surveillance with diet and lifestyle evaluation as a companion to noninvasive testing alternatives might support adopting a primary care rather than a secondary care service design for prevention interventions to address the risk of colorectal cancer (94, 95) .
In the future, there may be more scope for increased personalization of surveillance programs. Novel blood-based tests, such as predictive micro-RNAs or combined biomarkers (β-catenin nuclear localization, cyclooxygenase 2 expression, and 53-kDa protein (p53) nuclear expression), were significantly associated with adenoma recurrence after 3 years (ß-catenin: P = 0.002; cyclooxygenase 2: P = 0.001; p53: P = 0.001). These tests put forward predictions of adenoma recurrence with a high negative predictive value (88.5%) and sensitivity (94.6%) that, if validated, would be equivalent to or better than current clinical risk stratification approaches based on adenoma size and frequency (28, 32) .
Clinical issues
The most clinically relevant issue raised by this review is that of the role of aspirin chemoprevention, recently endorsed by the updated US Preventative Task Force recommendations (96) and described as the first pharmacological agent to be endorsed for cancer chemoprevention (97) . We have highlighted that aspirin combined with colonoscopy surveillance results in a reported ICER of $60,942/LYS (recalculated to be $73,927/LYS), in what we might reasonably infer to be high-risk groups and might be considered a strategy for personalized surveillance. Because some methodological issues were raised in the model reviewed within this paper, we believe it is highly relevant to consider an updated model that addresses the role of aspirin, taking cognizance of the known likelihood of a future precision medicine approach that is based on aspirin's mechanism of action.
The other key clinical issue highlighted in the review was how readily results may be affected by differences in capacity of colonoscopy services or may be influenced by other quality assurance issues such as adenoma detection rates. As shown in other evaluations of screening, the adenoma detection rate was recognized as influencing the cost-effectiveness of screening programs (84) . There are recognized differences in this rate between screening and surveillance, which was significantly higher in surveillance colonoscopies (37%), compared with screening colonoscopies (25%) (P < 0.001) (24) . Future work acknowledging the impact of examination quality, as characterized by adenoma detection rates, within decision models or colonoscopy capacity planning would allow robust evaluation of the benefits of surveillance. In so doing, we can more fully evaluate if infrequent high-quality colonoscopy examinations are indeed more effective in preventing colorectal cancer than are frequent low-quality colonoscopy examinations (35) .
Limitations
Potential limitations of the review are that, as a result of our search strategy, we do not characterize the gray literature related to the economic evaluation of surveillance in colorectal adenoma postpolypectomy surveillance.
Conclusion
We suggest a cautious interpretation of the findings of cost-effectiveness of colonoscopy-based postpolypectomy surveillance because of the small number of studies addressing the topic. On the basis of the reviewed literature, we would suggest that future investigations update and confirm the benefits reported, in particular exploring comparisons of the cost-effectiveness of newer testing alternatives, such as FIT or newer tests like micro-RNA. In particular, we suggest examination of where FIT may provide clinically accessible adjustments to cut-off levels and triage national or regional resources optimally based on national or regional quality indicators and capacity. Insights on the costeffectiveness of combined aspirin and colonoscopy merit further exploration in light of the updated literature on the role of aspirin in chemoprevention and its likely role in the prevention of premature mortality due to other causes. Taken together, these results suggest that there are valuable alternatives to current guidelines that should be explored in updated cost-effectiveness models.
